Daré Bioscience Secures $908K NIH Grant to Advance Preterm Birth Prevention Program — Daré Bioscience, Inc.

Event summary

Daré Bioscience received a $908,000 grant from NICHD to advance DARE-PTB2, an investigational program for preventing preterm birth.
The grant includes potential for an additional $1.3 million in future-year support for preclinical studies.
DARE-PTB2 aims to address a significant unmet medical need with no FDA-approved therapeutic options currently available.
The program builds on previous NICHD funding of $400,000 received in July 2023 for preclinical development.

The big picture

The NIH grant underscores the critical need for innovative solutions in women's health, particularly in preventing preterm birth, a leading cause of infant morbidity and mortality. Daré's ability to secure non-dilutive funding highlights its strategic focus on leveraging external support to advance its pipeline. The broader industry trend of increasing investment in women's health research suggests growing recognition of the unmet needs in this space.

What we're watching

Funding Execution: Whether Daré can effectively utilize the NIH grant to advance DARE-PTB2 through preclinical studies and secure the additional $1.3 million in future funding.
Regulatory Pathway: The pace at which DARE-PTB2 progresses from preclinical to clinical stages, given the lack of FDA-approved options for preterm birth prevention.
Strategic Focus: How Daré balances its focus on DARE-PTB2 with other programs in its women's health portfolio, particularly given the early-stage nature of this program.